THERAPEUTICSMD INC (TXMD) Stock Price & Overview

NASDAQ:TXMD • US88338N2062

2.3 USD
+0.05 (+2.22%)
Last: Mar 9, 2026, 08:00 PM

The current stock price of TXMD is 2.3 USD. Today TXMD is up by 2.22%. In the past month the price increased by 0.44%. In the past year, price increased by 217.15%.

TXMD Key Statistics

52-Week Range0.723 - 2.95
Current TXMD stock price positioned within its 52-week range.
1-Month Range2.07 - 2.54
Current TXMD stock price positioned within its 1-month range.
Market Cap
26.611M
P/E
230.00
Fwd P/E
13.26
EPS (TTM)
0.01
Dividend Yield
N/A

TXMD Stock Performance

Today
+2.22%
1 Week
+2.68%
1 Month
+0.44%
3 Months
+31.43%
Longer-term
6 Months +107.28%
1 Year +217.15%
2 Years +0.44%
3 Years -38.67%
5 Years -96.57%
10 Years -99.28%

TXMD Stock Chart

THERAPEUTICSMD INC / TXMD Daily stock chart

TXMD Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to TXMD. When comparing the yearly performance of all stocks, TXMD is one of the better performing stocks in the market, outperforming 97.89% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
TXMD Full Technical Analysis Report

TXMD Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to TXMD. The financial health of TXMD is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TXMD Full Fundamental Analysis Report

TXMD Earnings

Next Earnings DateMar 25, 2026
Last Earnings DateNov 12, 2025
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
TXMD Earnings History

TXMD Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y0%
Revenue Next Year1.11%
TXMD Forecast & Estimates

TXMD Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

TXMD Financial Highlights

Over the last trailing twelve months TXMD reported a non-GAAP Earnings per Share(EPS) of 0.01. The EPS increased by 102.21% compared to the year before.


Income Statements
Revenue(TTM)2.80M
Net Income(TTM)302.00K
Industry RankSector Rank
PM (TTM) 10.8%
ROA 0.78%
ROE 1.1%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%108.74%
Sales Q2Q%43.33%
EPS 1Y (TTM)102.21%
Revenue 1Y (TTM)75.19%
TXMD financials

TXMD Ownership

Ownership
Inst Owners29.3%
Shares11.57M
Float11.39M
Ins Owners1.62%
Short Float %0.41%
Short Ratio0.5
TXMD Ownership

TXMD Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO28.85934.238B
JNJ JOHNSON & JOHNSON20.83579.34B
MRK MERCK & CO. INC.22.63286.278B
PFE PFIZER INC8.98153.814B
BMY BRISTOL-MYERS SQUIBB CO9.57122.779B
ZTS ZOETIS INC17.2951.259B
RPRX ROYALTY PHARMA PLC- CL A8.8726.195B
VTRS VIATRIS INC5.6716.304B
ELAN ELANCO ANIMAL HEALTH INC22.7611.614B
AXSM AXSOME THERAPEUTICS INC N/A8.303B
BLTE BELITE BIO INC - ADR N/A6.501B
TERN TERNS PHARMACEUTICALS INC N/A4.547B
AMRX AMNEAL PHARMACEUTICALS INC13.594.166B

About TXMD

Company Profile

TXMD logo image TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

Company Info

THERAPEUTICSMD INC

951 Yamato Road, Suite 220

Boca Raton FLORIDA 33431 US

CEO: Robert G. Finizio

Employees: 1

TXMD Company Website

TXMD Investor Relations

Phone: 15619611900

THERAPEUTICSMD INC / TXMD FAQ

What does THERAPEUTICSMD INC do?

TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).


What is the stock price of THERAPEUTICSMD INC today?

The current stock price of TXMD is 2.3 USD. The price increased by 2.22% in the last trading session.


Does TXMD stock pay dividends?

TXMD does not pay a dividend.


What is the ChartMill technical and fundamental rating of TXMD stock?

TXMD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Can you provide the number of employees for THERAPEUTICSMD INC?

THERAPEUTICSMD INC (TXMD) currently has 1 employees.


Can you provide the market cap for THERAPEUTICSMD INC?

THERAPEUTICSMD INC (TXMD) has a market capitalization of 26.61M USD. This makes TXMD a Nano Cap stock.